Page last updated: 2024-09-02

tesmilifene and Neoplasm Metastasis

tesmilifene has been researched along with Neoplasm Metastasis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dancey, J; Dent, S; Garin, A; Gelmon, K; Gorbunova, V; Jassem, J; Lebwohl, D; MacNeil, M; Marlin, S; Pearce, L; Pienkowski, T; Pluzanska, A; Pritchard, K; Reyno, L; Seymour, L; Tu, D; Voi, M; Walley, B	1
Dancey, J; Liu, J; Pater, J; Pritchard, KI; Reyno, L; Seymour, LK; Tu, D	1

Trials

2 trial(s) available for tesmilifene and Neoplasm Metastasis

Article	Year
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Phenyl Ethers; Platelet Aggregation Inhibitors; Quality of Life; Treatment Outcome	2004
Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast cancer research and treatment, 2006, Volume: 100, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Doxorubicin; Fatigue; Female; Health Status; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neurotoxicity Syndromes; Patient Compliance; Phenyl Ethers; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vomiting	2006

Article

Year

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Phenyl Ethers; Platelet Aggregation Inhibitors; Quality of Life; Treatment Outcome

2004

Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.

Breast cancer research and treatment, 2006, Volume: 100, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Doxorubicin; Fatigue; Female; Health Status; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neurotoxicity Syndromes; Patient Compliance; Phenyl Ethers; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vomiting

2006